Search results for "Long-Term Outcome"

showing 9 items of 19 documents

Long-term outcomes in men and women with ST-segment elevation myocardial infarction and incomplete reperfusion after a primary percutaneous coronary …

2019

Background The failure of reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI) is more frequent than considered previously. Aim To evaluate sex-related differences in long-term outcomes in patients with STEMI and incomplete infarct-related artery reperfusion after a primary percutaneous coronary intervention. Patients and methods Of consecutive 42 752 patients with STEMI hospitalized between 2009 and 2011 in Poland, we analyzed a group of 766 (35%) women and 1453 (65%) men with less than thrombolysis in myocardial infarction (TIMI) flow grade 3 following a primary percutaneous coronary intervention. Results In the 2-year follow-up, the mortality rate among…

Malesex differencesTime Factorsmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsPrevalenceRegistriesTreatment Failure030212 general & internal medicineMyocardial infarctionStrokeAged 80 and overIncidenceMortality rateHazard ratioGeneral MedicineMiddle Agedprimary percutaneous coronary interventionCardiologyFemaleCardiology and Cardiovascular Medicinelong-term outcomesTIMImedicine.medical_specialtyPatient ReadmissionRisk Assessment03 medical and health sciencesPercutaneous Coronary InterventionSex FactorsReperfusion therapyCoronary CirculationInternal medicinemedicineHumanscardiovascular diseasesAgedHeart Failurebusiness.industryPercutaneous coronary interventionHealth Status Disparitiesmedicine.diseaseST-segment elevation myocardial infarctionincomplete reperfusionHeart failureST Elevation Myocardial InfarctionPolandbusinessCoronary Artery Disease
researchProduct

Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (pCR) after primary chemotherapy.

2009

Abstract Learning Objectives After completing this course, the reader will be able to: Summarize the main risk factors for relapse in patients with T4 breast cancer after neoadjuvant chemotherapy.Evaluate the role of hormone receptors and HER-2 as determinants of risk of relapse after neoadjuvant treatment.Compare the difference in outcomes between patients who achieve less than pCR in relation to receptor status. This article is available for continuing medical education credit at CME.TheOncologist.com. Purpose. Pathological complete response (pCR) to primary chemotherapy is the main determinant for improved disease-free survival (DFS) and overall survival (OS). The primary endpoints of ou…

OncologyAdultCancer Researchmedicine.medical_specialtyTime FactorsSettore MED/06 - Oncologia MedicaReceptor ErbB-2Breast NeoplasmsVinorelbineDisease-Free SurvivalBreast cancerTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPathologicalMastectomyAgedNeoplasm StagingCisplatinStage IIIB breast cancerNeoadjuvant chemotherapyPathological responseLong-term outcomesbusiness.industryRadiotherapy DosageMiddle Agedmedicine.diseasePrognosisCombined Modality TherapySurvival RateRegimenTreatment OutcomeOncologyHormone receptorLymphatic MetastasisFemaleLymph Nodesbusinessmedicine.drugEpirubicinFollow-Up StudiesThe oncologist
researchProduct

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

2004

Hepatitis C virus chronic infection is currently the most common cause of end-stage liver disease. The benefit of antiviral therapy on liver histology and its impact on the long-term course of the disease has been extensively studied. However, the results are still equivocal and the overall assessment of treatment effect remains difficult to evaluate. Although the conclusions of the last National Institute of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues still remain unanswered. We review the available data by an evidence-based approach and conclude that: 1) peginterferon alfa is more effective than conventional interferon in …

Oncologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicineDrug DiscoverymedicineHumansViral hepatitis CRandomized Controlled Trials as TopicPharmacologyEvidence-Based Medicinebusiness.industryRibavirinLiver NeoplasmsHistological benefitHepatitis CHepatitis C Chronicmedicine.diseaseLong-term outcomeTreatment OutcomechemistryCombination treatmentImmunologybusinessPegylated interferonmedicine.drugCurrent pharmaceutical design
researchProduct

Correlation Between Smoking Paradox and Heart Rhythm Outcomes in Patients With Coronary Artery Disease Receiving Percutaneous Coronary Intervention

2022

BackgroundThe effect of smoking on short-term outcomes among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is controversial. However, little is known about the impact of smoking on long-term outcomes in patients with stable coronary artery disease (CAD) who receive PCI.MethodsA total of 2,044 patients with stable CAD undergoing PCI were evaluated. They were divided into two groups according to smoking status (current smokers vs. non-smokers). Baseline characteristics, exposed risk factors, angiographic findings, and interventional strategies were assessed to compare the long-term clinical outcomes between groups. Predictors for myocardial in…

long-term outcomestable coronary artery diseaseRC666-701percutaneous coronary interventionrisk factorsDiseases of the circulatory (Cardiovascular) systemsmoker's paradoxcardiovascular diseasesCardiology and Cardiovascular MedicineFrontiers in Cardiovascular Medicine
researchProduct

Long-term stability of early sudden gains in an acceptance and values-based intervention

2019

Though previous research has extensively reported that sudden gains are associated with superior treatment results, research on the long-term effects and stability of sudden gains is not as consistent. The current study explored the long-term stability of early sudden gains (ESGs) observed in a brief acceptance and values-based intervention for depression provided by novice therapists. The participants were 56 volunteers diagnosed with major depressive disorder. Among the participants, 23% experienced ESGs, i.e. they reached the status of improved or recovered in the Reliable Change Index (RCI; Jacobson & Truax, 1991) classification after only two sessions. The current study examined the le…

masennuslong-term outcome050103 clinical psychologyOrganizational Behavior and Human Resource Managementmedicine.medical_specialtyHealth (social science)hyväksymis- ja omistautumisterapiapitkäaikaisvaikutuksetTreatment resultsbrief intervention03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineIntervention (counseling)medicine0501 psychology and cognitive sciencesHopefulnessinterventioApplied PsychologyEcology Evolution Behavior and SystematicsDepression (differential diagnoses)Depressive symptoms05 social sciencesvarhainen äkillinen hyötyminennovice therapistsmedicine.disease030227 psychiatryTerm (time)opiskelijaterapeutitearly sudden gainshoitotuloksetdepressioninterventiohoitoPhysical therapyMajor depressive disorderPsychologyJournal of Contextual Behavioral Science
researchProduct

Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. A Global Expert Consensus Document

2019

© American Heart Association, Inc.

medicine.medical_specialtyGuiding PrinciplesSCORING SYSTEMmedicine.medical_treatmentPerforation (oil well)percutaneous coronaryRevascularizationMULTICENTER CTO REGISTRYCARDIOVERTER-DEFIBRILLATOR RECIPIENTSmethodsLONG-TERM OUTCOMESPROCEDURAL OUTCOMESPhysiology (medical)treatment outcome.INTRAVASCULAR ULTRASOUNDmedicineCOMPUTED-TOMOGRAPHYIntensive care medicineinterventionHEALTH-STATUStreatmentVENTRICULAR-ARRHYTHMIASbusiness.industrypercutaneous coronary interventionStentPercutaneous coronary interventionReentryRETROGRADE APPROACHcoronary occlusionCoronary occlusionConventional PCIoutcomeCardiology and Cardiovascular Medicinebusiness
researchProduct

Five-year outcomes following timely primary percutaneous intervention, late primary percutaneous intervention, or a pharmaco-invasive strategy in ST-…

2019

Abstract Aims ST-segment elevation myocardial infarction (STEMI) guidelines recommend primary percutaneous coronary intervention (pPCI) as the default reperfusion strategy when feasible ≤120 min of diagnostic ECG, and a pharmaco-invasive strategy otherwise. There is, however, a lack of direct evidence to support the guidelines, and in real-world situations, pPCI is often performed beyond recommended timelines. To assess 5-year outcomes according to timing of pPCI (timely vs. late) compared with a pharmaco-invasive strategy (fibrinolysis with referral to PCI centre). Methods and results The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) programme c…

medicine.medical_specialtyPercutaneousmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial InfarctionAcute myocardial infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineReperfusion therapyFibrinolytic Agents[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemFibrinolysismedicineHumansST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesTimingPrimary PCIbusiness.industryFibrinolysisHazard ratioPercutaneous coronary interventionmedicine.diseaseLong-term outcome3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV] Life Sciences [q-bio]Treatment OutcomeEmergency medicineConventional PCIST Elevation Myocardial InfarctionCardiology and Cardiovascular Medicinebusiness
researchProduct

Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-anal…

2019

Background & Aims: Risk for relapse after induction of remission with steroid therapy has been studied extensively in patients with autoimmune pancreatitis (AIP), but findings have been equivocal. We performed a systematic review and meta-analysis to estimate the relapse rate of AIP after initial remission after steroid treatment and to identify factors associated with relapse. Methods: Three reviewers searched MEDLINE, SCOPUS, and EMBASE until July 2018 to identify studies on rate of relapse of AIP after induction of remission with steroid therapy. A pooled estimate was calculated using the DerSimonian and Laird method for a random-effects model. This study was conducted in accordance …

medicine.medical_specialtyTime FactorsAutoimmune Pancreatitismedicine.medical_treatmentMEDLINEInflammation; Long-Term Outcome; Pancreas; Response To TreatmentSteroidlaw.invention03 medical and health sciences0302 clinical medicineMaintenance therapyRandomized controlled trialRecurrenceRisk FactorslawInternal medicinemedicineHumansPancreaIn patientGlucocorticoidsPancreasAutoimmune pancreatitisInflammationHepatologybusiness.industryRemission InductionResponse To TreatmentGastroenterologyLong-Term Outcomemedicine.diseaseSystematic review030220 oncology & carcinogenesisMeta-analysisChronic Disease030211 gastroenterology & hepatologybusinessFollow-Up StudiesClinical Gastroenterology and Hepatology
researchProduct

Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

2021

The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open sur…

medicine.medical_specialtymedicine.medical_treatmentaortic valve stenosis030204 cardiovascular system & hematologyTAVRnew-generation trans-catheter heart valvesProsthesisArticle03 medical and health sciences0302 clinical medicineValve replacementInternal medicinemedicine030212 general & internal medicineMyocardial infarctionStrokeEjection fractionbusiness.industryRGeneral Medicinemedicine.diseaseStenosisAortic valve stenosisCardiologyMedicineImplantbusinesslong-term outcomesJournal of Clinical Medicine
researchProduct